WHOQOL-100, a 100 items quality of life assessment by WHO is too lengthy to be applicable in researches where the quality of life is one of the many variables of interest. The abbreviated version with 26 items is more acceptable by subjects, especially those with illness. The generic and the abbreviated Malay version were given to subjects who were healthy and with illness. Results showed that the domain scores produced by WHOQOL-BREF correlate highly with that of WHOQOL-100. WHOQOL-BREF domain scores demonstrated good discriminant validity, construct validity, internal consistency and test-retest reliability. The study indicates that WHOQOL-BREF in its brevity offers a valid and reliable assessment of quality of life.
Brachionus plicatilis is used to feed fish and crustacean larvae in the aquaculture industry. It is well established that the type of microalgae may influence rotifer production. This experiment was conducted to determine the effect of five different locally available microalgae species at Fisheries Research Institute (FRI), Kampung Pulau Sayak, Kedah, Malaysia on the instantaneous growth rate (μ) of rotifer. Nannochloris sp., Tetraselmis sp., Isochrysis sp., Chlorella sp., and Nannochloropsis sp. were used as feed at different algae densities (0.1, 0.3, 0.7 and 1.5 × 106 cells/ml) and culture volumes (20, 70 and 210 ml). At algae densities ranging from 0.3 to 1.5 × 106 cells/ml, an average μ value of more than 0.90 per day were recorded for all algae species. However, at density of 0.1 × 106 cells/ml, only Tetraselmis sp. resulted in the significantly highest μ value compared with others (p < 0.05). In terms of volume, smaller culture volume of Tetraselmis sp. (20 ml) showed significantly higher μ compared with higher volume (70 and 210 ml cultures).
The purpose of this study is to review the relationship between the highly anticipated concept of circular economy (CE) and sustainable development goals (SDGs). These two sustainability principles have transformed organizations and countries in their quest to achieve sustainable development. Despite their importance to the business and corporate realm, the discussion of these two concepts has been developed in silos, arbitrarily connected. Through a bibliometric approach, this study reviewed 226 journal publications and 16,008 cited references from the Web of Science (WoS) to understand the past, present and future trends of the two concepts and their impact on the sustainability development. The bibliometric approach of citation, co-citation and co-word analysis uncovers the relevant and significant themes and research streams. Theoretical and practical implications were discussed within the broader business and governance perspective to develop a substantial triple bottom line in creating a sustainable future for civil society.
This article reviews available evidence regarding hypertension management in the Asia-Pacific region, focussing on five research questions that deal with specific aspects: blood pressure (BP) control, guideline recommendations, role of renin-angiotensin-aldosterone system (RAAS) inhibitors in clinical practice, pharmacological management and real-world adherence to guideline recommendations. A PubMed search identified 2537 articles, of which 94 were considered relevant. Compared with Europeans, Asians have higher systolic/diastolic/mean arterial BP, with a stronger association between BP and stroke. Calcium channel blockers are the most-commonly prescribed monotherapy in Asia, with significant variability between countries in the rates of angiotensin-converting enzyme inhibitors (ACEis)/angiotensin-receptor blockers (ARBs) and single-pill combination (SPC) use. In clinical practice, ARBs are used more commonly than ACEis, despite the absence of recommendation from guidelines and clinical evidence supporting the use of one class of drug over the other. Ideally, antihypertensive treatment should be tailored to the individual patient, but currently there are limited data on the characteristics of hypertension in Asia-Pacific individuals. Large outcome studies assessing RAAS inhibitor efficacy and safety in multi-national Asian populations are lacking. Among treated patients, BP control rates were ~ 35 to 40%; BP control in Asia-Pacific is suboptimal, and disproportionately so compared with Western nations. Strategies to improve the management of hypertension include wider access/availability of affordable treatments, particularly SPCs (which improve adherence), effective public health screening programs targeting patients to drive health-seeking behaviours, an increase in physician/patient awareness and early implementation of lifestyle changes. A unified Asia-Pacific guideline on hypertension management with pragmatic recommendations, particularly in resource-limited settings, is essential.
Dyslipidaemia is highly prevalent in the Malaysian population and is one of the main risk factors for atherosclerotic cardiovascular disease (ASCVD). Low-density lipoprotein cholesterol (LDL-C) is recognised as the primary target of lipid-lowering therapy to reduce the disease burden of ASCVD. Framingham General CV Risk Score has been validated in the Malaysian population for CV risk assessment. The Clinical Practice Guidelines (CPG) on the management of dyslipidaemia were last updated in 2017. Since its publication, several newer randomised clinical trials have been conducted with their results published in research articles and compared in meta-analysis. This underscores a need to update the previous guidelines to ensure good quality care and treatment for the patients. This review summarises the benefits of achieving LDL-C levels lower than the currently recommended target of < 1.8mmol/L without any safety concerns. In most high and very high-risk individuals, statins are the first line of therapy for dyslipidaemia management. However, certain high-risk individuals are not able to achieve the LDL-C goal as recommended in the guideline even with high-intensity statin therapy. In such individuals, lower LDL-C levels can be achieved by combining the statins with non-statin agents such as ezetimibe and PCSK9 inhibitors. Emerging non-statin lipid-lowering therapies and challenges in dyslipidaemia management are discussed in this article. The review also summarises the recent updates on local and international guidelines for dyslipidaemia management.